Post transplant erythrocytosis (PTE) is a known complication after renal transplantation, seen in 10-15% of cases.
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Its occurrence has not been reported following allogeneic hemopoietic stem cell transplant (HSCT), though a case of polycythemia vera following ASCT has recently been mentioned. 2 We report erythrocytosis in three cases of acquired severe aplastic anemia following allogeneic HSCT.
The first patient was a 24-year-old man who underwent peripheral blood HSCT from an HLA-matched brother on 19 July 2001 after conditioning with antilymphocyte globulin (ALG) 15 mg/kg per day Â 3 plus CY 50 mg/kg per day Â 4. GVHD prophylaxis was with CYA plus prednisolone. Except for mild CYA-induced reversible renal impairment, his post transplant course was uneventful. Immunosuppressives were stopped 15 months post transplant. In January 2005, 42 months post transplant, he developed malaise, headache and plethora. Physical examination was normal. His Hb value was 17.5 g per 100 mL, Hct level was 52%, WBC and plt counts were normal. His chest X-ray, ECG, echocardiogram, renal and liver ultrasound scans, i.v. urography, O 2 saturation and arterial blood gases were normal. All the causes of secondary polycythemia were ruled out. Serum EPO levels were 4.9 mIU/mL (normal 3.3-16.6). Red cell mass was 38.98 mL/kg (normal 30-35). PCR result for JAK-2 mutation was negative. STR analysis showed complete donor chimerism and donors blood counts were normal.
The second patient was a 12-year-old male child who had allogeneic peripheral blood HSCT from an HLA-matched sister aged 8 years on 17 March 2003 after conditioning with ALG plus CY. GVHD prophylaxis was given with CYA, prednisolone and short MTX. Patient had primary graft failure and second HSCT using BM infusion was done on 24 April 2003 following conditioning with fludarabine 30 mg/m 2 per day Â 4, antithymocyte globulin (ATG) 3.75 mg/kg per day Â 4 and CY 300 mg/m 2 per day Â 4. Except for CYA-induced moderate hypertension, his early post transplant course was unremarkable. Immunosuppressives were stopped 18 months post transplant. On 12 December 2006, 44 months post transplant, he reported with lassitude and plethora. His Hb value was 18.2 g per 100 mL, Hct level was 53.5%, WBC and plt counts were normal. All the causes for secondary polycythemia were ruled out by relevant investigations. Red cell mass was 38.21 mL/kg, and serum EPO levels were 8.3 mIU/mL. JAK-2 mutation analysis was negative. STR analysis revealed complete donor chimerism, and donor had normal blood counts.
Our third patient was a 24-year-old man who had BMT from a matched sibling donor on 8 April 2005, after conditioning with ALG and CY. GVHD prophylaxis was given with CYA, prednisolone plus short MTX. During the post transplant course, he continued to have persistently low blood counts for which he received pulses of prednisolone. This patient also had mild CYA-induced reversible renal impairment. Immunosuppressives were stopped 15 months post HSCT. He was seen on 8 November 2008 (43 months post transplant) with complaints of headache and plethora. His Hb value was 17.5 g per 100 mL, Hct level was 51.8%. All the investigations for secondary polycythemia were normal. JAK-2 mutation analysis was negative. Serum EPO level was 2.6 mIU/mL. All the three patients were non-smokers, and were not taking steroids or any other drug. They are being managed with phlebotomies to keep Hct level o50%. Figures 1 and  2 show Hb profile of patients 1 and 2, respectively. PTE has been defined as persistently elevated Hct to a level greater than 51% after renal transplantation, 1 with reported prevalence ranging from 5-17%. 3, 4 Its association with HSCT has not been reported. Since 2001 we have carried out more than 140 HSCT in aplastic anemia. In all, 29 of the patients were adolescent and young men more than 3 years post transplant. Erythrocytosis has been seen in three cases so far.
PTE has been reported to occur between 3 and 60 months 5 post renal transplant, most cases occurring 8-24 months post transplant. 1 In our patients, erythrocytosis developed 42, 44 and 43 months post HSCT. So far we have not encountered this complication in patients undergoing allogeneic HSCT for conditions other than aplastic anemia. Reported predisposing factors in PTE are male gender and smoking, in addition to renal factors such as retention of native kidneys and transplant artery stenosis. 1, 5 All our patients were men, non-smokers, not exposed to high altitude with no pre or post transplant renal, lung, hepatic or cardiac pathology. All had true erythrocytosis with an increase in the red cell mass above the normal. Although all our patients were men, significance of gender as a risk factor cannot be weighed reasonably as 75% of all our patients undergoing transplant for aplastic anemia were men.
The relatively low levels of EPO in our patients suggest intact feedback mechanisms of EPO production and point towards other mechanisms such as increased sensitivity of the erythroid progenitors to EPO or abnormal stromal factors. In vitro study of erythroid progenitor cells to observe the pattern of expression of angiotensin II type I receptors, a potential area of investigation, was not carried out because of lack of facilities. Endogenous androgens may have some role, as all the three patients were men.
Some authors 6 have suggested that PTE developed more frequently in those renal graft recipients who received CYA, others 7 have failed to support this finding. All our patients received CYA for GVHD prophylaxis for a period of 15-18 months.
Post transplant hypertension is an important factor for the development of PTE. 5 Our patients had high blood pressure while on CYA therapy after transplant; however, they were normotensive before transplant and at the time of developing erythrocytosis. We have not documented any spontaneous remission so far.
In conclusion, post allogeneic HSCT erythrocytosis appears to be an unusual albeit benign complication occurring in a specific subgroup of HSCT recipients. As more of our HSCT recipients survive beyond 40 months post transplant it might be possible to fully characterize, identify predisposing factors, understand pathogenic mechanisms and find out an eventual outcome of the condition.
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